---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-106919"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:42:39.166530+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# INmune Bio extends shareholder rights plan to Dec 2025 and grants stock options to executives and directors

## Summary
- Rights Agreement amended to extend expiration to December 30, 2025.
- Non-employee directors each granted options for 32,500 shares at $5.05, vesting Dec 5, 2026.
- CEO Raymond Tesi granted options for 226,000 shares at $5.05, vesting Dec 5, 2026.
- CFO David Moss granted 223,000 options; CSO Mark Lowdell 140,000 options, same terms.
- All grants expire December 4, 2034 and were made under the 2021 Stock Incentive Plan.

## SEC filing metadata
- accession: 0001213900-24-106919
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024106919/0001213900-24-106919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024106919/ea0223776-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-106919
- JSON: https://secwatch.observer/filing/0001213900-24-106919.json
- Plain text: https://secwatch.observer/filing/0001213900-24-106919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.